Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Historical Holders from Q4 2018 to Q3 2025

Symbol
CLDX on Nasdaq
CUSIP
15117B202
Type / Class
Equity / Common Stock, par value $.001
Shares outstanding
65.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
70.7M
Holdings value
$1.83B
% of all portfolios
0.003%
Grand Portfolio weight change
0%
Number of holders
173
Number of buys
86
Number of sells
-82
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 11.1% +40% $191M $55.9M 7.39M +41.3% Wellington Management Group LLP Oct 31, 2025
Kynam Capital Management, LP 9.79% +27% $104M $22.9M 6.5M +28.4% Kynam Capital Management, LP Mar 31, 2025
FMR LLC 7.3% $77.4M 4.86M FMR LLC Dec 31, 2024
BlackRock, Inc. 7.3% -12.5% $76.8M -$10.5M 4.82M -12.1% BlackRock, Inc. Mar 31, 2025
Point72 Asset Management, L.P. 6.7% $84.4M 4.46M Point72 Asset Management, L.P. Jul 2, 2025
Bellevue Group AG 5.4% $93.6M 3.62M Bellevue Group AG Aug 18, 2025
Commodore Capital LP 4.6% -8% $78.3M -$8.32M 3.03M -9.6% Commodore Capital LP Sep 30, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% -36% $61.6M -$30.4M 2.38M -33% T. Rowe Price Associates, Inc. Sep 30, 2025
EVENTIDE ASSET MANAGEMENT, LLC 2% $30.6M 1.36M Eventide Asset Management, LLC Jun 30, 2025

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 70.7M $1.83B -$41M $25.87 173
2025 Q2 72.7M $1.48B -$19M $20.35 178
2025 Q1 73.6M $1.34B -$25.5M $18.15 170
2024 Q4 73.7M $1.86B -$10.9M $25.27 172
2024 Q3 71.8M $2.44B +$61.9M $33.99 181
2024 Q2 69.6M $2.58B +$1.54M $37.01 181
2024 Q1 69.3M $2.91B +$374M $41.97 197
2023 Q4 22.9K $908K +$170K $39.66 2
2023 Q3 50.6M $1.39B -$662K $27.52 139
2023 Q2 50.2M $1.7B +$19.5M $33.93 147
2023 Q1 49.5M $1.78B +$25M $35.98 156
2022 Q4 48.7M $2.17B -$3.35M $44.57 160
2022 Q3 49M $1.37B +$39.8M $28.11 142
2022 Q2 48.2M $1.29B -$45.8M $26.96 145
2022 Q1 49.6M $1.68B +$106M $34.06 156
2021 Q4 43.2M $1.66B +$98.8M $38.64 168
2021 Q3 43.1M $2.31B +$390M $53.99 155
2021 Q2 35.6M $1.18B +$48M $33.44 126
2021 Q1 34.5M $709M -$32.5M $20.60 110
2020 Q4 36.3M $637M +$70.5M $17.52 116
2020 Q3 32.1M $470M +$66.7M $14.83 79
2020 Q2 27.8M $356M +$311M $13.00 61
2020 Q1 3.91M $5.82M -$78.4K $1.66 29
2019 Q4 3.9M $7.91M +$19.4K $2.23 32
2019 Q3 3.68M $7.48M +$711K $2.13 38
2019 Q2 155K $1.54K -$443K $2.68 3
2019 Q1 2.6M $12M +$11.5M $4.92 38
2018 Q4 100K $20K +$20K $0.20 1